Hologic, Inc. saw increased investments and a stock upgrade after reporting a 4.5% revenue rise.

Barclays and other hedge funds increased their stakes in Hologic, Inc., which reported $1.01 EPS and $987.90 million in revenue for the third quarter, up 4.5% year-over-year. Analysts predict an EPS of 4.28 for the current year. BNP Paribas upgraded the stock to "strong-buy," and the consensus rating is "Moderate Buy" with a target price of $89.50. Hologic's market cap is $17.04 billion.

3 months ago
5 Articles